Form 8-K - Current report:
SEC Accession No. 0000950170-25-077865
Filing Date
2025-05-27
Accepted
2025-05-27 17:20:07
Documents
10
Period of Report
2025-05-20
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vktx-20250520.htm   iXBRL 8-K 77030
  Complete submission text file 0000950170-25-077865.txt   180810

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vktx-20250520.xsd EX-101.SCH 23918
12 EXTRACTED XBRL INSTANCE DOCUMENT vktx-20250520_htm.xml XML 4545
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

EIN.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37355 | Film No.: 25989961
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)